human anxa1 elisa kit Search Results


human anxa1 (annexin a1) elisa kit  (Guangzhou JET Bio-Filtration)
94
Guangzhou JET Bio-Filtration human anxa1 (annexin a1) elisa kit
Human Anxa1 (Annexin A1) Elisa Kit, supplied by Guangzhou JET Bio-Filtration, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+anxa1+elisa+kit/custom%40e-el-h5512%4032823596?v=Guangzhou+JET+Bio-Filtration
Average 94 stars, based on 1 article reviews
human anxa1 (annexin a1) elisa kit - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier
human annexin a1 (anxa1) elisa kit  (Bioss)
N/A
   Buy from Supplier
human anxa1 commercial elisa kit  (Elabscience Biotechnology)
93
Elabscience Biotechnology human anxa1 commercial elisa kit
Fig. 1. <t>ANXA1</t> level in CSF sample of control group and SPMS patient. Bar graph related to ANXA1 measurement using standard ELISA assay that represents means ± SD measured in each group. A comparison between the results from control group and SPMS patient was done using a t-test. ELISA experiments were repeated at least three times. ** indicates: P < 0.01.
Human Anxa1 Commercial Elisa Kit, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+anxa1+elisa+kit/10__34172_slash_bi__30264-42-0-5?v=Elabscience+Biotechnology
Average 93 stars, based on 1 article reviews
human anxa1 commercial elisa kit - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
annexin a1  (Boster Bio)
93
Boster Bio annexin a1
Dynamics of plasma DAMP levels in advanced lung cancer patients during the first cycle of systemic anticancer therapy. (A) Time course of the fold change in plasma concentrations (relative to baseline) of HMGB1, CRT, HSP70, <t>annexin</t> <t>A1,</t> and histone H3 in individual patients. Plasma samples were collected before and on days 3 and 8 after the onset of the first cycle as well as before the onset of the second cycle of treatment. (B) Fold change in the plasma levels of HMGB1, CRT, HSP70, annexin A1, and histone H3 during the first treatment cycle relative to baseline. Data are means + SEM. The P values for differences in mean values were determined by repeated-measures ANOVA. (C) Comparison of baseline values and maximum values after the onset of the first cycle of treatment for the fold change in plasma levels of the five DAMPs. The numbers of patients showing a >2-fold increase were 34, 34, 24, 5, and 3 for HMGB1, CRT, HSP70, annexin A1, and histone H3, respectively. CRT and histone H3 were undetectable at baseline in 10 and 97 patients, respectively, and these patients were excluded from the analysis. The P values for differences in mean values were determined with the paired t test. DAMP, damage-associated molecular pattern; HMGB1, high-mobility group box 1; CRT, calreticulin; HSP70, heat shock protein 70; SEM, standard error of the mean; ANOVA, analysis of variance.
Annexin A1, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+anxa1+elisa+kit/pmc08264341-89-16-19?v=Boster+Bio
Average 93 stars, based on 1 article reviews
annexin a1 - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
human annexin a1 anxa1 elisa kit  (OriGene)
N/A
For quantitative detection of human Annexin A1 in cell culture supernates serum and plasma heparin EDTA
   Buy from Supplier
uncoated human anxa1 (annexin a1) elisa kit  (Elabscience Biotechnology)
N/A
   Buy from Supplier
elisa kit anxa1 human  (G Biosciences)
N/A
An ELISA kit for the detection of ANXA1 Human This uses Sandwich ELISA Double Antibody and has a sensitivity of 0 188ng ml
   Buy from Supplier
human anxa1 annexin a1 elisa kit  (Elabscience)
N/A
   Buy from Supplier
human annexin a1 (anxa1) assaymax elisa kit  (Assaypro)
N/A
Human Annexin A1 (ANXA1) AssayMax ELISA Kit
   Buy from Supplier

Image Search Results


Fig. 1. ANXA1 level in CSF sample of control group and SPMS patient. Bar graph related to ANXA1 measurement using standard ELISA assay that represents means ± SD measured in each group. A comparison between the results from control group and SPMS patient was done using a t-test. ELISA experiments were repeated at least three times. ** indicates: P < 0.01.

Journal: BioImpacts

Article Title: Annexin A1, calreticulin and high mobility group box 1 are elevated in secondary progressive multiple sclerosis: Does immunogenic cell death occur in multiple sclerosis?

doi: 10.34172/bi.30264

Figure Lengend Snippet: Fig. 1. ANXA1 level in CSF sample of control group and SPMS patient. Bar graph related to ANXA1 measurement using standard ELISA assay that represents means ± SD measured in each group. A comparison between the results from control group and SPMS patient was done using a t-test. ELISA experiments were repeated at least three times. ** indicates: P < 0.01.

Article Snippet: Human ANXA1 commercial ELISA Kit (Elabscience; E-EL-H5512) was used to determine the level of ANXA1.

Techniques: Control, Enzyme-linked Immunosorbent Assay, Comparison

Dynamics of plasma DAMP levels in advanced lung cancer patients during the first cycle of systemic anticancer therapy. (A) Time course of the fold change in plasma concentrations (relative to baseline) of HMGB1, CRT, HSP70, annexin A1, and histone H3 in individual patients. Plasma samples were collected before and on days 3 and 8 after the onset of the first cycle as well as before the onset of the second cycle of treatment. (B) Fold change in the plasma levels of HMGB1, CRT, HSP70, annexin A1, and histone H3 during the first treatment cycle relative to baseline. Data are means + SEM. The P values for differences in mean values were determined by repeated-measures ANOVA. (C) Comparison of baseline values and maximum values after the onset of the first cycle of treatment for the fold change in plasma levels of the five DAMPs. The numbers of patients showing a >2-fold increase were 34, 34, 24, 5, and 3 for HMGB1, CRT, HSP70, annexin A1, and histone H3, respectively. CRT and histone H3 were undetectable at baseline in 10 and 97 patients, respectively, and these patients were excluded from the analysis. The P values for differences in mean values were determined with the paired t test. DAMP, damage-associated molecular pattern; HMGB1, high-mobility group box 1; CRT, calreticulin; HSP70, heat shock protein 70; SEM, standard error of the mean; ANOVA, analysis of variance.

Journal: Translational Lung Cancer Research

Article Title: Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer

doi: 10.21037/tlcr-21-92

Figure Lengend Snippet: Dynamics of plasma DAMP levels in advanced lung cancer patients during the first cycle of systemic anticancer therapy. (A) Time course of the fold change in plasma concentrations (relative to baseline) of HMGB1, CRT, HSP70, annexin A1, and histone H3 in individual patients. Plasma samples were collected before and on days 3 and 8 after the onset of the first cycle as well as before the onset of the second cycle of treatment. (B) Fold change in the plasma levels of HMGB1, CRT, HSP70, annexin A1, and histone H3 during the first treatment cycle relative to baseline. Data are means + SEM. The P values for differences in mean values were determined by repeated-measures ANOVA. (C) Comparison of baseline values and maximum values after the onset of the first cycle of treatment for the fold change in plasma levels of the five DAMPs. The numbers of patients showing a >2-fold increase were 34, 34, 24, 5, and 3 for HMGB1, CRT, HSP70, annexin A1, and histone H3, respectively. CRT and histone H3 were undetectable at baseline in 10 and 97 patients, respectively, and these patients were excluded from the analysis. The P values for differences in mean values were determined with the paired t test. DAMP, damage-associated molecular pattern; HMGB1, high-mobility group box 1; CRT, calreticulin; HSP70, heat shock protein 70; SEM, standard error of the mean; ANOVA, analysis of variance.

Article Snippet: The plasma levels of CRT (#ELH-CALR-1; RayBiotech, Peachtree Corners, GA), HSP70 (#KE00059; Proteintech, Tokyo, Japan), and annexin A1 (#EK1745; Boster Biological Technology, Pleasanton, CA) were similarly quantified with ELISA kits.

Techniques: Clinical Proteomics, Comparison

Association between the maximum fold change in plasma DAMP levels relative to baseline and clinical response. The maximum fold change in HMGB1 (A), CRT (B), HSP70 (C), or annexin A1 (D) levels is shown as the mean + SEM for patients classified according to tumor response. The numbers of patients who showed a CR, PR, SD or PD according to RECIST criteria were 1, 43, 63, and 13, respectively; one patient not evaluable by RECIST criteria was excluded from the analysis. CRT was undetectable at baseline in seven patients with a PR, in two with SD, and in one with PD, and these patients were also excluded from the analysis. The P values for differences in mean values were determined by one-way ANOVA. DAMP, damage-associated molecular pattern; HMGB1, high-mobility group box 1; CRT, calreticulin; HSP70, heat shock protein 70; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; RECIST, Response Evaluation Criteria in Solid Tumors; ANOVA, analysis of variance.

Journal: Translational Lung Cancer Research

Article Title: Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer

doi: 10.21037/tlcr-21-92

Figure Lengend Snippet: Association between the maximum fold change in plasma DAMP levels relative to baseline and clinical response. The maximum fold change in HMGB1 (A), CRT (B), HSP70 (C), or annexin A1 (D) levels is shown as the mean + SEM for patients classified according to tumor response. The numbers of patients who showed a CR, PR, SD or PD according to RECIST criteria were 1, 43, 63, and 13, respectively; one patient not evaluable by RECIST criteria was excluded from the analysis. CRT was undetectable at baseline in seven patients with a PR, in two with SD, and in one with PD, and these patients were also excluded from the analysis. The P values for differences in mean values were determined by one-way ANOVA. DAMP, damage-associated molecular pattern; HMGB1, high-mobility group box 1; CRT, calreticulin; HSP70, heat shock protein 70; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; RECIST, Response Evaluation Criteria in Solid Tumors; ANOVA, analysis of variance.

Article Snippet: The plasma levels of CRT (#ELH-CALR-1; RayBiotech, Peachtree Corners, GA), HSP70 (#KE00059; Proteintech, Tokyo, Japan), and annexin A1 (#EK1745; Boster Biological Technology, Pleasanton, CA) were similarly quantified with ELISA kits.

Techniques: Clinical Proteomics

Maximum fold changes in plasma DAMP concentrations according to anticancer treatment modality. The maximum fold change in HMGB1 (A), CRT (B), HSP70 (C), or annexin A1 (D) levels is shown as the mean + SEM for patients with a CR (n=1) or a PR (n=43). Treatment modalities included platinum doublet chemotherapy (n=22), single-agent chemotherapy (n=3), CCRT (n=11), and EGFR- or ALK-TKIs (n=8). CRT was undetectable at baseline in four patients receiving platinum doublet chemotherapy, one receiving single-agent chemotherapy, and two receiving CCRT, and these patients were excluded from the analysis. The P values for differences in mean values were determined by one-way ANOVA. DAMP, damage-associated molecular pattern; HMGB1, high-mobility group box 1; CRT, calreticulin; HSP70, heat shock protein 70; SEM, standard error of the mean; CR, complete response; PR, partial response; CCRT, concurrent chemoradiotherapy; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; TKI, tyrosine kinase inhibitor; ANOVA, analysis of variance.

Journal: Translational Lung Cancer Research

Article Title: Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer

doi: 10.21037/tlcr-21-92

Figure Lengend Snippet: Maximum fold changes in plasma DAMP concentrations according to anticancer treatment modality. The maximum fold change in HMGB1 (A), CRT (B), HSP70 (C), or annexin A1 (D) levels is shown as the mean + SEM for patients with a CR (n=1) or a PR (n=43). Treatment modalities included platinum doublet chemotherapy (n=22), single-agent chemotherapy (n=3), CCRT (n=11), and EGFR- or ALK-TKIs (n=8). CRT was undetectable at baseline in four patients receiving platinum doublet chemotherapy, one receiving single-agent chemotherapy, and two receiving CCRT, and these patients were excluded from the analysis. The P values for differences in mean values were determined by one-way ANOVA. DAMP, damage-associated molecular pattern; HMGB1, high-mobility group box 1; CRT, calreticulin; HSP70, heat shock protein 70; SEM, standard error of the mean; CR, complete response; PR, partial response; CCRT, concurrent chemoradiotherapy; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; TKI, tyrosine kinase inhibitor; ANOVA, analysis of variance.

Article Snippet: The plasma levels of CRT (#ELH-CALR-1; RayBiotech, Peachtree Corners, GA), HSP70 (#KE00059; Proteintech, Tokyo, Japan), and annexin A1 (#EK1745; Boster Biological Technology, Pleasanton, CA) were similarly quantified with ELISA kits.

Techniques: Clinical Proteomics

Correlation analysis for maximum fold changes in plasma DAMP concentrations. (A,B,C,D,E,F) Correlation analysis for HMGB1 and either CRT (A), HSP70 (B), or annexin A1 (C), for CRT and either HSP70 (D) or annexin A1 (E), or for HSP70 and annexin A1 (F) is shown. The correlation coefficient (r) and corresponding P values are indicated. CRT was undetectable at baseline in 10 patients, and these patients were excluded from the analysis. (G) Venn diagram for the numbers of patients showing a >2-fold increase in the plasma levels of HMGB1, CRT, or HSP70 during the first treatment cycle. DAMP, damage-associated molecular pattern; HMGB1, high-mobility group box 1; CRT, calreticulin; HSP70, heat shock protein 70.

Journal: Translational Lung Cancer Research

Article Title: Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer

doi: 10.21037/tlcr-21-92

Figure Lengend Snippet: Correlation analysis for maximum fold changes in plasma DAMP concentrations. (A,B,C,D,E,F) Correlation analysis for HMGB1 and either CRT (A), HSP70 (B), or annexin A1 (C), for CRT and either HSP70 (D) or annexin A1 (E), or for HSP70 and annexin A1 (F) is shown. The correlation coefficient (r) and corresponding P values are indicated. CRT was undetectable at baseline in 10 patients, and these patients were excluded from the analysis. (G) Venn diagram for the numbers of patients showing a >2-fold increase in the plasma levels of HMGB1, CRT, or HSP70 during the first treatment cycle. DAMP, damage-associated molecular pattern; HMGB1, high-mobility group box 1; CRT, calreticulin; HSP70, heat shock protein 70.

Article Snippet: The plasma levels of CRT (#ELH-CALR-1; RayBiotech, Peachtree Corners, GA), HSP70 (#KE00059; Proteintech, Tokyo, Japan), and annexin A1 (#EK1745; Boster Biological Technology, Pleasanton, CA) were similarly quantified with ELISA kits.

Techniques: Clinical Proteomics